News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Data from Sequenta’s LymphoSIGHTTM Platform for the Detection of Minimal Residual Disease Presented at the European Hematology Association Meeting


6/15/2012 10:22:13 AM

SAN FRANCISCO--(BUSINESS WIRE)--Sequenta, Inc. announced today that data demonstrating the power of its DNA sequencing-based LymphoSIGHTTM platform for the detection of Minimal Residual Disease (MRD) was presented during the European Hematology Association (EHA) meeting in Amsterdam June 15.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES